Novartis: Increase patient reach in LMICs with its innovative medicines by 200% by 2025, and boost reach of its flagship global health programs (for leprosy, malaria, Chagas, sickle cell) by 50%. This translates to over 23 million patients reached by 2025 through access initiatives.
J&J: Support at least 1 million frontline health workers by 2030 via training and capacity-building. Additionally, through its Health for Humanity Goals, J&J has pledged ambitious targets like enabling 700,000 patients to access bedaquiline for multidrug-resistant TB by 2025 (potentially averting 6 million new MDR-TB infections).
Sanofi: Provide care for over 2 million patients with chronic diseases by 2030 in 40 of the world’s poorest countries by making 30 essential Sanofi medicines (for diabetes, cardiovascular disease, TB, malaria, cancer, etc.) available in 40 low-income countries on a nonprofit basis. Sanofi also seeks improve diabetes care for 300,000 insulin-dependent patients by 2030, reaching 20 times more patients in 2030 than in 2021.
Roche: Doubling patient access by 2023. In its pharma division, Roche’s goal is to double the number of patients receiving its innovative medicines in LMICs by 2026. In diagnostics, it plans to double the reach of high medical value diagnostic solutions by 2030.
GSK: GSK’s broad vision is to ‘positively impact the health of 2.5 billion people’ by the end of the decade (2030)’ through its medicines and vaccines.
Novo Nordisk: Proclaims that “no child should die from type 1 diabetes,” and is expanding its Changing Diabetes in Children program to reach 100,000 children with type 1 diabetes by 2030.